Coming Off HRT

Educational only. Not medical advice. Do not stop HRT abruptly without discussing a tapering strategy with your clinician. Abrupt discontinuation can cause symptom rebound. If you are considering stopping, have the conversation first.

Stopping HRT is a conversation, not an event. It involves understanding what will happen when you remove the hormonal support your body has been relying on, deciding whether the reasons for stopping outweigh the benefits of continuing, and doing it in a way that minimizes rebound symptoms and protects what HRT has been maintaining.

Some women stop because a clinician recommended discontinuation at a specific time point. Some stop because a risk factor changed. Some stop because they want to see whether their body has moved past the symptomatic window naturally. Whatever the reason, stopping should be a planned, informed choice. It should not happen because your prescription lapsed or someone told you “you have been on it long enough.”

• Vasomotor symptoms return in approximately 50% of women after stopping HRT, regardless of how long they were on it
• Symptoms are most likely to return if they were severe before starting and if you are still within the typical symptomatic window (median 7.4 years, sometimes 10+)
• Gradual tapering over 3-6 months reduces the severity of symptom rebound compared to abrupt discontinuation
• Bone density declines rapidly after stopping HRT. Approximately 3 to 5% loss occurs in the first 1 to 2 years, at rates similar to early postmenopause
• Vaginal estrogen can and should be continued after stopping systemic HRT. It is a different clinical decision with a different risk profile
• Stopping HRT is not a one-way door. If symptoms return and the benefit-risk balance remains favorable, restarting is an option

When you stop systemic HRT, your body returns to the postmenopausal hormonal state. Estrogen levels drop to endogenous postmenopausal levels (typically below 20 pg/mL). The thermoregulatory center in the hypothalamus may become destabilized again, triggering hot flashes. This can happen even in women who had been symptom-free on HRT for years.

Vasomotor symptoms. Return in roughly 50% of women. The rebound is typically most intense in the first 2-4 weeks after the last dose (or after completing a taper) and may diminish over weeks to months. Some women experience rebound symptoms that are worse than their original symptoms before HRT, though this is usually temporary. Women who had mild original symptoms and have been on HRT for many years are less likely to experience significant rebound - they may have naturally moved past the symptomatic window.

Vaginal and urinary symptoms. Return and progress. Unlike vasomotor symptoms, which often eventually resolve on their own, genitourinary symptoms of menopause (GSM) are progressive without estrogen. Stopping systemic HRT means vaginal tissue will begin to atrophy again. This is the strongest argument for continuing vaginal estrogen after discontinuing systemic therapy.

Bone density. Declines at accelerated rates after stopping HRT - approximately 3 to 5% bone mineral density loss in the first 1 to 2 years. This is comparable to the accelerated bone loss seen in early postmenopause. Women who were on HRT partly for bone protection should discuss transition to a bone-specific agent (bisphosphonate or denosumab) when stopping. Without a transition plan, years of bone protection can be lost rapidly.

Mood, sleep, and cognitive symptoms. May return if they were hormonally driven and the hormonal deficit that caused them persists. Women who experienced significant mood or cognitive improvement on HRT should factor this into the discontinuation decision.

Gradual dose reduction over 3 to 6 months is preferred over abrupt discontinuation.

Option 1: stepwise dose reduction. Reduce estrogen dose by 50% for 2 to 3 months, then reduce again by 50% for another 2-3 months, then stop. For example: 1 mg oral estradiol becomes 0.5 mg for 3 months, then stop. Or a 0.05 mg patch becomes 0.025 mg for 3 months, then stop.

Option 2: interval extension. Increase the time between doses or patch changes. Twice-weekly patch becomes weekly for 2 to 3 months, then every 10 days for 2 to 3 months, then stop. Daily oral becomes every other day for 2 to 3 months, then every third day, then stop.

Option 3: switch to lower-potency formulation. Transition from systemic HRT to vaginal-only estrogen, which addresses GSM while discontinuing systemic effects.

Continue progesterone as long as you are taking systemic estrogen. Stop progesterone when systemic estrogen is fully discontinued (assuming you are not using it for a separate indication like sleep).

New contraindication develops. New breast cancer diagnosis, VTE event, significant cardiovascular event, or other condition that shifts the risk-benefit calculation.

Risk profile changes. Age, new comorbidities, or new medications that alter the benefit-risk balance.

Testing whether symptoms have resolved. After several years on HRT, some women’s natural vasomotor symptoms have resolved. A supervised taper can reveal whether HRT is still providing symptomatic benefit or is being continued out of habit.

Personal preference. An informed decision to discontinue after understanding the implications is a valid choice.

Because of an arbitrary time limit. There is no evidence-based maximum duration for HRT. If symptoms persist, risk factors have not changed, and the benefit-risk balance remains favorable, continuing is appropriate.

Because a non-specialist told you to stop. If you are being managed by a clinician with menopause expertise and another provider (cardiologist, oncologist, PCP) suggests stopping, facilitate a conversation between providers rather than simply complying.

Because you “should not be on hormones at your age.” This is not supported by current clinical guidelines. Duration decisions should be individualized.

Low-dose vaginal estrogen for genitourinary symptoms has no recommended maximum duration. Systemic absorption is minimal. The symptoms it treats are progressive without treatment and do not resolve with time. NAMS, ACOG, and the Endocrine Society all support continuing vaginal estrogen indefinitely when clinically indicated.

If you stop systemic HRT, continue vaginal estrogen. This should be a separate, explicit decision in your discontinuation plan.

• What is the clinical rationale for stopping now versus continuing?
• How should we taper, and over what timeline?
• If my vasomotor symptoms return, can I restart?
• Should I transition to a bone-specific agent to protect the bone density I have maintained?
• Should I continue vaginal estrogen after stopping systemic HRT?
• What symptoms should prompt me to contact you during the taper?